DiaMedica Therapeutics Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
DiaMedica Therapeutics Inc. (DMAC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $515.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-30
- DiaMedica Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $515.00K, a 88.64% increase from fiscal 2024.
- DiaMedica Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $273.00K, a 33.25% decline from fiscal 2023.
- DiaMedica Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $409.00K, a 20.29% increase from fiscal 2022.
- DiaMedica Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $340.00K, a 19.24% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $515.00K 10-K · filed 2026-03-30 | |
| 2024-12-31 | $273.00K 10-K · filed 2026-03-30 | $491.00K 10-K · filed 2025-03-17 |
| 2023-12-31 | $409.00K 10-K · filed 2025-03-17 | |
| 2022-12-31 | $340.00K 10-K · filed 2024-03-19 | |
| 2021-12-31 | $421.00K 10-K · filed 2023-03-28 | |
| 2020-12-31 | $498.00K 10-K · filed 2022-03-14 | |
| 2019-12-31 | $315.00K 10-K · filed 2021-03-10 | |
| 2018-12-31 | $243.00K 10-K · filed 2020-03-23 | |
| 2017-12-31 | $110.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |